Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

Kyaw Z Thein; Siqing Fu; Filip Janku; Apostolia M Tsimberidou; Sarina A Piha-Paul; Daniel D Karp; Jatin Shah; Denái R Milton; Jing Gong; Selma Sulovic; Lacey McQuinn; Bettzy A Stephen; Rivka R Colen; Brett W Carter; Funda Meric-Bernstam; Aung Naing

doi:10.36401/JIPO-21-20

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

J Immunother Precis Oncol. 2022 Feb 9;5(1):10-12. doi: 10.36401/JIPO-21-20. eCollection 2022 Feb.

Authors

Kyaw Z Thein^{1

2}, Siqing Fu¹, Filip Janku¹, Apostolia M Tsimberidou¹, Sarina A Piha-Paul¹, Daniel D Karp¹, Jatin Shah³, Denái R Milton⁴, Jing Gong¹, Selma Sulovic¹, Lacey McQuinn¹, Bettzy A Stephen¹, Rivka R Colen⁵, Brett W Carter⁶, Funda Meric-Bernstam¹, Aung Naing¹

Affiliations

¹ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Division of Hematology and Medical Oncology, Oregon Health and Science University/Knight Cancer Institute, Portland, OR, USA.
³ Karyopharm Therapeutics, Newton, MA, USA.
⁴ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Keywords: carboplatin; metastatic solid tumors; pemetrexed; selective inhibitor of nuclear export (SINE); selinexor.

Grants and funding

Source of Support: This study was supported by Karyopharm Therapeutics, Clinical and Translational Sciences Award [1UL1TR003167] National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS), and MD Anderson Cancer Support Grant [P30CA016672] National Institutes of Health/National Cancer Institute (NIH-NCI).